CeriBell (NASDAQ:CBLL) Reaches New 1-Year High - Here's What Happened

Key Points

• CeriBell shares reached a new 52-week high of $28.19, closing near $27.60 and lifting the company’s market capitalization to approximately $1.07 billion.
• Analyst sentiment is generally positive: CeriBell has a consensus “Moderate Buy” rating and a $27.00 average price target, while TD Cowen raised its target to $33.00.
• The company exceeded quarterly revenue expectations but missed on earnings, reporting revenue of $28.1 million and an adjusted loss of $0.51 per share; insiders have sold roughly $4.3 million of stock over the past three months.

Shares of CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) reached a new 52-week high on Thursday. The stock traded as high as $28.19 and last traded at $27.5960, with a volume of 64,614 shares. The stock had previously closed at $27.22.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. TD Cowen raised their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Barclays raised shares of CeriBell to a "neutral" rating in a research note on Tuesday, August 18th. BTIG Research restated a "buy" rating and set a $30.00 price target on shares of CeriBell in a report on Friday, September 11th. Canaccord Genuity Group increased their price target on CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of CeriBell from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, CeriBell presently has an average rating of "Moderate Buy" and a consensus target price of $27.00.

CeriBell Stock Performance

The firm's 50 day moving average price is $24.82 and its 200-day moving average price is $20.77. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -15.79 and a beta of 0.94. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. The company had revenue of $28.10 million for the quarter, compared to the consensus estimate of $27.28 million. On average, analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Insider Transactions at CeriBell

In other news, CFO Scott Blumberg sold 1,521 shares of CeriBell stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $36,534.42. Following the sale, the chief financial officer directly owned 146,600 shares in the company, valued at approximately $3,521,332. The trade was a 1.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Xingjuan Chao sold 20,846 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $25.03, for a total transaction of $521,775.38. Following the completion of the transaction, the chief executive officer directly owned 746,345 shares of the company's stock, valued at $18,681,015.35. This trade represents a 2.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 174,905 shares of company stock worth $4,312,995. 17.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CeriBell

A number of hedge funds have recently modified their holdings of CBLL. Strs Ohio acquired a new stake in shares of CeriBell during the 1st quarter worth about $27,000. Legal & General Group Plc acquired a new position in CeriBell in the second quarter worth $53,000. State of Wyoming acquired a new position in CeriBell in the first quarter worth $62,000. Quantbot Technologies LP bought a new stake in shares of CeriBell during the second quarter worth $112,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of CeriBell during the first quarter worth $341,000.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company's primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.